Adverse reactions and risk factors of immune checkpoint inhibitors in the treatment of non-small cell lung cancer
10.3760/cma.j.cn371439-20230404-00108
- VernacularTitle:免疫检查点抑制剂在非小细胞肺癌治疗中的不良反应及危险因素
- Author:
Juanjun DENG
1
;
Dayong ZHAO
;
Miao LI
Author Information
1. 青海大学临床医学院，西宁 810000
- Keywords:
Carcinoma, non-small-cell lung;
Immune checkpoint inhibitors;
Therapy;
Drug-related side effects and adverse reactions;
Risk factors
- From:
Journal of International Oncology
2023;50(9):564-568
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors (ICIs) have been widely used in the treatment of non-small cell lung cancer (NSCLC) . However, ICIs related pneumonia, myocarditis, rash, colitis, nervous system immune-related adverse events (irAEs) , as well as hypothyroidism, ocular irAEs, liver irAEs, etc., can be generated in the process of use, and some irAEs are even fatal. Systemic inflammatory biomarkers as well as chemotherapy, higher body mass index, epidermal growth factor receptor mutation are risk factors for its occurrence. The common irAEs and risk factors are analyzed in order to improve the clinician's understanding of ICIs.
